CA
NZ
UK
AU
IND
US
The reduction reflects a deliberate effort to free cash for strategic investments while reinforcing the firm’s balance sheet.
Industrials stocks are under scrutiny as earnings season kicks off in mid-2026, with corporate insiders holding back on major moves amid rising geopolitical and monetary policy risks. The sector faces a delicate balance between steady economic performance and external threats, including the ongoing conflict …
Genprex (NASDAQ: GNPX) will implement a 1:22 reverse stock split at market open on July 16, 2026. The move consolidates every 22 shares of common stock into one share, reducing the total outstanding from 11,108,577 to approximately 504,936. The par value of $0.001 per …
A hedge fund’s strong quarterly performance has brought AnaptysBio into focus, illustrating the high-stakes nature of biotech investing. The firm’s shares have seen notable appreciation as it transitions to a royalty-based business model, a strategy that has gained traction among clinical-stage biotechs seeking to …
Immunic Inc. (NASDAQ: IMUX) provided new insights into its lead asset, vidofludimus calcium, which targets progressive multiple sclerosis. The July 14, 2026, presentation positions the therapy as a key focus for the company’s neurology pipeline, addressing a segment of the disease with limited treatment …
Inhibikase Therapeutics (NASDAQ: IKT) announced a corporate update through a regulatory filing on July 14, 2026. The disclosure focused on capital-raising efforts via its at-the-market (ATM) offering mechanism. The filing adhered to requirements under the Securities Exchange Act of 1934.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) has detailed a refreshed approach to research and development, concentrating on its advanced programs and forthcoming pipeline candidates. The information was presented at a recent corporate briefing.
Wall Street analysts are recalibrating expectations for Alnylam Pharmaceuticals as the RNA interference therapeutics sector undergoes significant shifts. These adjustments reflect broader changes in the biotech environment, particularly for companies developing treatments for rare and progressive diseases like transthyretin amyloidosis (ATTR).
Medical device stocks gained momentum after AngioDynamics reported stronger-than-expected Q4 2026 earnings, signaling resilience in the healthcare sector. The results lifted investor sentiment toward companies specializing in vascular and minimally invasive technologies, with ripple effects across related equities.
Edwards Lifesciences Corp. (NYSE: EW) has been hit with a $10 million penalty for antitrust violations related to its $115 million acquisition of JC Medical. The Federal Trade Commission also fined JC Medical $2 million, marking the largest combined penalty ever for failing to …
Please wait processing your request...